Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice summary 2morrowsGains. Thanks. I fully agree. The market will now start to wake up and start to take notice of AEMD.
After some short term traders, and others, sell their shares this morning, in the mid .40s, my bet is that we will see a solid climb higher today.
about 130K shares at the ask, followed by about 66K just above the (visible) ask. nice first 3 minutes.
steady trend upwards,over the next weeks, and months, should take firm hold beginning the next few trading days. The kind of short lived spike in share price we saw last October is not what I would expect here.
Best wishes to all AMED longs
BBarry
link to Membrana
http://www.membrana.de/about/center.htm
A brief summary of 8 disclosures from presentation
This info will no doubt be available later when these new powerpoints are accessible on Aethlons’s website. But here is a quick summary. Please excuse the typos.
8 disclosures
1.) a new research study on Breast Cancer. Dr Doug Taylor Univ. Louisville
data expected within 60 days
2.) new study in process, in vitro study of Lymphoma
3.) a compassionate care case, involving EndStage Lunch Cancer Human patient at hosital in South Africa. Results still to be analyzed
4.) A tuberculosis study. Funded by Gates Foundation Grant
In Vitro study showed 97% capture of TB exsomes within 4 hours
5.) India: Drug Controller (gov’t agency) has cleared Hemopurifier for import
6.) India: recent GMP production run, 100 cartridges shipped
7.) India: announced work with Medanta Center: a new Medical Tourism Institution
- a $360M facility
- 1600 beds
- (I missed the figure) I think it was 20 operating rooms, or something like that
- 10 minutes from New Delhi airport
- add’l disclosures coming
8.) a Manufacturing Partnership: Membrana Gmbh based in Germany
we have letter of intent signed. Very large scale manufacturer of dialysis equipment.
Membrana is a division of PolyPore International (NYSE: PPO)
Aethlon retains control of all Intellectual Property
Partnership will provide scalable production upwards to very large numbers of units
That last slide included a mention of Membrana providing clinical trial support in EU
If I’ve missed key points on these disclosures, please add or correct.
Sure seems like it was a very great presentation, with a lot of substantive milestones, on multiple fronts.
Great day for all patient longs
BBarry
Strong volume buying into close yesterday. Very encouraging.
Prior to the "couple of small buys at the end" we had a 50K block at .40 at 3:26PM followed by 20K at .42, and some other multi thousand share buys that brought us back up. On a mostly down day (for most of the day) in the broader markets, I think it is worth noting that we saw about 97K shares trade, all at or above .40 during the final 34 minutes of the day.
I would have called any close at or above .40 today to be a sign of some encouraging strength, after last weeks gains.
If we were to go sideways for a couple days now, and show some signs of stability above .40, that could be a good thing as we later approach next weeks news.
I'm among those very encouraged to see the market starting to respond positively to what we're expecting to hear next week.
This morning's SEC filing contains slides for the CMDI presentation this week at the Rodman & Renshaw Conf. That conference plus recent PRs may generate some buying this week.
AEMD mention in San Diego "Xconomy" News website
San Diego Biotechs Raise Cash for Novel Drugs to Treat Cancers, Broad Disease Spectrum
Bruce V. Bigelow 3/2/10
A number of biotechs and medical device companies in the San Diego area have disclosed funding deals in recent weeks. As I noted last month, San Diego-based ProActa raised about $1.1 million to continue its anti-cancer drug development work. I found some more deals while reviewing filings submitted to the Securities and Exchange Commission:
. . .
—Aethlon Medical (OTCBB: AEMD) has raised $600,000 from an unnamed investor, according to a recent SEC filing. The investor provided $300,000 in cash and a $300,000 loan to acquire 660,000 shares of Aethlon’s common stock. The San Diego-based company has been developing a blood purification device, the Hemopurifier, as a broad-spectrum therapy against infectious viral pathogens. In October, Aethlon formed a subsidiary, Exosome Sciences. The company says Exosome Sciences will run tests to see if the Hemopurifier also is effective in capturing exosomes that are secreted by solid tumors, lymphomas, and leukemias to suppress the patient’s immune response.
. . .
http://www.xconomy.com/san-diego/2010/03/02/san-diego-biotechs-raise-cash-for-novel-drugs-to-treat-cancers-broad-disease-spectrum/
Half of today's volume, was in the last hour. 65% in the last 2 hours. Not overwhelming volume, but given the relatively low volume of much of the last two weeks, today's end of day might be an encouraging sign.
In fact, last Friday's trading included some larger block trades that pushed the price up, a little, as well.
Next couple days should be interesting.
BBarry
re the stockcharts.com chart that humblehawk posted, when I add their metric of accum/dist and look at that along with the Chaikin Money Flow indicator, the two together give a technical confirmation of the accumulation that we've been seeing in recent weeks. Even while the share price has been flat for a couple weeks, the stockcharts (and other site's) measures of accumulation are recently bullish on AEMD.
best wishes for a happy AEMD new year.
BBarry
Super encouraging. Multiple key points in newsletter. Below I break out the key points, since each of these points, could be worthy of solid positive share price reaction. Taken together, I find it very encouraging indeed!
- now established our GMP manufacturing processes.
- kicked-off our inaugural production run yesterday
- our HCV human studies documented average per-treatment viral load reductions of 29-42%. achieved in the absence of SOC therapy!
- initial commercialization remains focused towards treating individuals infected with Hepatitis-C virus (HCV) at select medical centers in India
- which should allow… first Hemopurifier® shipments in February
Aethlon Medical Releases Shareholder Letter
Press Release
Source: Aethlon Medical, Inc.
On 8:00 am EST, Tuesday December 8, 2009
To our Shareholders:
In my September 15th shareholder letter, I indicated that we initiated the program with Bioserv/NextPharma to produce our Hemopurifier® under good manufacturing practice (GMP) requirements set forth in quality system (QS) regulations for medical device commercialization. Today, I am pleased to report that we have now established our GMP manufacturing processes. Furthermore, we kicked-off our inaugural production run yesterday, which should allow us to commence with our first Hemopurifier® shipments in February. The task of establishing manufacturing of our Hemopurifier® under GMP was an intricate process requiring significant expertise and a focused commitment among many participants. I applaud the tireless efforts of Dr. Richard Tullis, Paul Duffin, and our colleagues at Bioserv/NextPharma.
The initial commercialization of our Hemopurifier® remains focused towards treating individuals infected with Hepatitis-C virus (HCV) at select medical centers in India. At present, fewer than half of HCV-infected individuals who initiate the 48-week interferon-ribavirin standard of care (SOC) drug regimen successfully respond to treatment. With an estimated 180 million people infected worldwide, a monumental need exists for adjunct therapies that can improve HCV cure rates without increasing the considerable toxicity already associated with SOC therapy. In this regard, we have established a data-supported strategy that provides an opportunity to play a central and enduring role in HCV care. Our strategy uniquely positions our Hemopurifier® to enhance the benefit of SOC therapy even if the drug combinations underlying SOC become redefined.
While our Hemopurifier® is the first-in-class device to selectively capture viruses and immunosuppressive proteins from circulation, the precedent for a device to treat HCV was established by Asahi Kasei Kuraray Medical (Asahi), who validated that moderate levels of viral filtration at the outset of SOC therapy improves cure rates. Asahi demonstrated that their multi-cartridge approach, which is marketed in Japan as V-RAD, was able to achieve 71.4% cure rates in HCV patients who previously failed SOC therapy. In Asahi's studies, V-RAD was administered once daily for three consecutive days at the outset of SOC therapy and provided an average viral load reduction of 26.1% during each treatment period, which averaged 3 1/4 hours in duration. Amazingly, such outcomes were achieved without a further need for viral filtration during the remaining 47+ weeks of SOC therapy.
On October 30th, we reported HCV treatment outcomes at the 42nd Annual American Society of Nephrology (ASN) Conference. When analyzing Hemopurifier® treatment data from all of our HCV human studies, we documented average per-treatment viral load reductions of 29-42%. While the length of each Hemopurifier® treatment was similar in duration to V-RAD, the Hemopurifier® did not benefit from SOC associated viral load reductions as our results were achieved in the absence of SOC therapy. We acknowledge and appreciate that V-RAD has indeed documented that viral filtration improves HCV treatment outcomes. However, we believe the Hemopurifier® delivers the necessary capabilities to establish broad-market acceptance of medical device in infectious disease care. Foremost of these capabilities is our ability to selectively capture infectious viruses and immunosuppressive proteins not addressed by V-RAD. The selective capture of deleterious agents from circulation establishes an environment that permits continuous or aggressive intermittent treatment strategies that can truly optimize patient outcomes. Whereas historic therapeutic filtration approaches, including V-RAD, are restricted in scope as they indiscriminately remove particles from blood by molecule size. As a result, the safe application of such treatments remains limited as beneficial blood components required for health are removed along with the deleterious target.
In the face of a challenging economic climate, we have reached a pivotal stage that positions us to capitalize on the sum of our efforts during the last decade. We have not deviated in our vision to evolve what once existed as a theoretical concept into the reality of a device that could change the lives of those afflicted with HCV and other infectious disease conditions. On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
I’m not expecting a shareholder letter… I remain very long, and have added shares in the past few weeks. I’m expecting a trend of substantive PRs, within the next 8 weeks, on several of the milestones (partnership, India, etc) that we're all wanting to see.
I think that the several news items of the past 10 or 12 weeks, represent a new trend, where we will see real news, not Shareholder letters. I may be wrong, but that is my guess.
Thanks GWMAN for your ongoing many contributions here.
GLTA
BBarry
that was 3:39 Eastern Time , not share price
I just purchased 4000 shares at 3:39. Might buy a little more if I can.
a flaw in interpreting the aging A/R trend here. The fact that each of the older 30 day periods has lower total A/R outstanding can't be used to interpet a recent month by month growth in total sales. You don't want to assume that the totals reported for the 30-60 and 60-90 aged periods represents ALL sales for those respective periods. Presumably some receivables have come in during those older periods. Hence, those reported A/R figures are NOT the total sales for each of those older periods.
Overall, the rest of the ER looks very encouraging.
otherwise, thanks Fernando for your many many helpful posts on various stocks.
Barry
8KA filed this morning !!!! part of that form, included below
This current report on Form 8-K/A amends and restates in its entirety the current report on Form 8-K of L&L International Holdings, Inc. dated October 29, 2009 filed with the Securities and Exchange Commission on October 29, 2009. The only amendments reflected in this Form 8-K/A are (i) the correction of the coal washing facilities and the additional equity ownership interest relating to the Notes (as defined below), (ii) the refiling of Exhibit 10.1 and (iii) the date on the signature page has been changed to November 4, 2009 .
Item 1.01 Entry into a Material Definitive Agreement
L & L International Holdings, Inc. (the “Registrant” or “L&L”) executed that certain Acquisition and Capital Increase Agreement (hereinafter the “Agreement”), effective October 23, 2009, with Hon Shen Coal Co. Ltd. (“Hon Shen”), which is located in Yunnan Province, China. Presently, Hon Shen has two distinctive operations; a) coal washing, and b) coking operations. Pursuant to the Agreement, L&L will increase its equity ownership interest in Hon Shen’s coal washing facilities from a 65% equity ownership interest to a 93% equity ownership interest. In addition, L&L will own 93% equity interest in Hon Shen’s coking facilities, thus reaching an overall 93% ownership of both Hon Shen’s coal washing and coking operations.
That abstract was written in the necessarily very conservative language of scientists. That is consistent with what would be presented with most of the topics at today’s Nephrology Conference.
The Great news, as has been stated before, is that we have a respected MD (not the well spoken and respected JJ) presenting actual data results of clinical application of the hemopurifier. Notice that Dr Kher is the first name listed in the abstract, while JJ is not listed by name as a speaker. Although surely JJ will be present, and active where appropriate. This conference presentation is a great milesone, in a larger unfolding story regarding commercialization of AEMD products in India and elsewhere.
If anyone was expecting business strategy or investment news related to commercialization in India today, that would not have been appropriate for the audience at the Nephrology conference. Sure, it would be nice to get such news concurrent with today’s presentation, but … it sure seems we have seen a lot of evidence to indicate that such news is coming, relatively soon. Those who were looking for lots of unknowns to be answered in a new PR today, are probably selling today.
I’m looking forward to the coming week, the coming weeks, and the rest of 2009, for more good news re AEMD.
My thanks to the helpful sharing on this board.
BBarry
My sense of Level 2 on Fidelity Active Trader is that what I'm shown is only bids and asks by MMs for orders of 2500 shares or greater. Lower share-count thresholds are used for higher priced stocks.
I've had no doubt in the past that there were other bids and asks not visible to my Level 2 view.
This may be similar to what other broker systems are showing.
Barry
Fidelity ActiveTrader level2 same as what was just reported showing on Ameritrades. Ask still showing as NITE .51 then ARCA AND HDSN both at .60 then UBSS at .62
Amazing that Mr Bill has the arrogance to bash a poster who offers extensive substance in his many posts. While, Mr Bill offers no substance, just shows up and tries to start a fight.
could very well be 'all of the above', of the sum total of the reasons you mention. One thing that becomes obvious with the increased visibility of the range of applications possible with the hemopurifier, is that AEMD is NOT a one-trick pony. That fact, combined with the bargain level share price versus the potential of even just a part of any one of these market opps is what is driving the buying.
regarding Friday's Nephrology Conf presentation by the MD from India; if we see results that are considered (just)'good', then that would be great news as we are in need of real-world clinical results. If the results are powerfully positive, then even more of a further boost for shareprice and visibility of AEMD.
Barry
I can’t help but wonder about any possible role of the USAMRID resources being assigned the task of: 1.) expedite further H1N1 testing of the hemopurifier and 2.) helping to consult on a hastily arranged emergency manufacture of H1N1/hemopurifiers.
My thoughts are perhaps wildly speculative here, but I do recall that USAMRID resources were applied to help Northrup Grumman (NOC) and Cepheid (CPHD) to move into high volume production of Anthrax Testing equipment for the US Postal Service around 2002-2003.
USAMRID, which is already working with AEMD, has lots of resources. I would think that some of the folks within USAMRID might be asking the same questions about H1N1 & the Hemopurifier. ???
Thanks to all who have posted helpful info here.
BBarry